Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for EYPT.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2007. Start Trial.
Date Value
June 30, 2026 -62.35M
March 31, 2026 -80.55M
December 31, 2025 -65.05M
September 30, 2025 -59.35M
June 30, 2025 -62.59M
March 31, 2025 -53.12M
December 31, 2024 -35.85M
September 30, 2024 -39.03M
June 30, 2024 -20.18M
March 31, 2024 -31.17M
December 31, 2023 -23.11M
September 30, 2023 -15.20M
June 30, 2023 57.02M
March 31, 2023 -16.84M
December 31, 2022 -12.59M
September 30, 2022 -13.14M
June 30, 2022 -19.12M
March 31, 2022 -20.16M
December 31, 2021 -16.67M
September 30, 2021 -7.787M
June 30, 2021 -10.54M
March 31, 2021 -15.10M
December 31, 2020 5.895M
September 30, 2020 1.136M
June 30, 2020 -5.121M
Date Value
March 31, 2020 -16.34M
December 31, 2019 -11.49M
September 30, 2019 -14.77M
June 30, 2019 -17.11M
March 31, 2019 -13.33M
December 31, 2018
September 30, 2018
June 30, 2018
March 31, 2018
June 30, 2017 -4.452M
March 31, 2017 -4.543M
December 31, 2016 -5.009M
September 30, 2016 -6.486M
June 30, 2016 -4.347M
March 31, 2016 -4.302M
December 31, 2015 -3.174M
September 30, 2015 -4.493M
June 30, 2015 -3.006M
March 31, 2015 -3.954M
December 31, 2014 21.25M
September 30, 2014 -3.994M
June 30, 2014 -2.785M
March 31, 2014 -1.852M
December 31, 2013 -2.257M
September 30, 2013 -3.777M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Ocular Therapeutix, Inc. -67.27M
Eli Lilly & Co. 10.69B
Elanco Animal Health, Inc. 277.00M
Amylyx Pharmaceuticals, Inc. -31.42M
Nuvation Bio, Inc. -42.97M